Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau -- Ignore unavailable to you. Want to Upgrade?

To: BulbaMan who wrote (217)	8/18/2000 10:54:18 AM
From: scaram(o)uche	Respond to of 2243

a start...... <CAPTION> Number of Percent of Name and Address Shares of Outstanding Shares of of Beneficial Owner Common Stock Common Stock /(1)/ - ---------------------------------------- -------------- --------------------- <S> <C> <C> Joseph K. Adlerstein, Ph.D. 1,738,334/(2)/ 34.0% c/o SpectruMedix Corporation 2124 Old Gatesburg Road State College, Pennsylvania 16803 Judy K. Mencher 50,000/(3)/ 1.2% c/o DDJ Capital Management 141 Linden Street, Suite 4 Wellesley, MA 02482 Bernard Sonnenschein 338,219 8.0% 1519 49th Street Brooklyn, New York 11219 Stephen J. Wertheimer 100,000 2.4% 15 Steeple Chase Greenwich, Connecticut 08631 PE Corporation 800,000/(4)/ 15.8% 761 Main Avenue Norwalk, CT 06859 All directors and executive officers 1,888,334/(5)/ 36.6% As a group (3 persons) </TABLE>

To: BulbaMan who wrote (217)	8/18/2000 10:56:03 AM
From: scaram(o)uche	Respond to of 2243

don't have time to look closer now. this doesn't inspire confidence, but there has to be reason that PE is a large shareholder........ Joseph K. Adlerstein co-founded SpectruMedix in April 1992. Dr. Adlerstein has been President and Chief Executive Officer and a member of the Board of Directors of SpectruMedix since its formation. Dr. Adlerstein has over 20 years of experience with high-tech companies focusing on energy, the environment, bioengineering, pharmaceuticals, ultrasonics and metallurgy. Prior to founding SpectruMedix, Dr. Adlerstein served as an officer, director and principal of Kasiel Holdings Ltd. (a member of the Adir Group), a real estate and construction firm. Dr. Adlerstein received a B.S. from City University of New York, a Masters in Physics from New York University and a Ph.D. in Physics from the Massachusetts Institute of Technology. Judy K. Mencher has been a member of the Board of Directors since March 2000. Ms. Mencher also serves on the Audit Committee and the Compensation Committee of the Board of Directors. Since 1996 she has been a principal at DDJ Capital Management, LLC, which was founded in 1996. Since 1997 she has been a member of the board of directors for Waste Systems International, Inc. From 1990 to 1996, Ms. Mencher was employed by Fidelity Investments. Before joining Fidelity, Ms. Mencher was a partner at the law firm of Goodwin, Procter & Hoar LLP. Stephen Wertheimer has been a member of the Board of Directors since January 2000. Mr. Wertheimer also serves on the Audit Committee and the Compensation Committee of the Board of Directors. Since August 1999, Mr. Wertheimer provided consulting services to SpectruMedix. Since 1996, Mr. Wertheimer has been a managing director of Credit Research & Trading LLC. Mr. Wertheimer is also the chairman of Advanced Mining Systems, Inc. and serves as a director of El Paso Electric Company, Greenwich Fine Arts, Inc. and Trikon Technologies, Inc. From 1991 to 1997, Mr. Wertheimer served as president of Water Capital Corp., a company he founded in 1991.

To: BulbaMan who wrote (217)	7/25/2001 1:09:14 PM
From: tuck	Read Replies (1) \| Respond to of 2243

BulbaMan, You've been quiet of late. I see SMDX has recent news and finally, a reasonable spread. Trickle is thinking of taking a little flier here with its limited cash. >>New York, New York, Jul 10, 2001 (Market News Publishing via COMTEX) -- SpectruMedix Corporation announced that it has received a $1 million capital infusion from New York investor Ilan Reich, and that Mr. Reich had assumed the offices of Chairman and Chief Executive Officer, effective immediately. Mr. Reich replaces Dr. Joseph Adlerstein in those positions. Dr. Adlerstein will no longer be associated with SpectruMedix. The I. Reich Family Limited Partnership, an entity affiliated with Mr. Reich, has purchased 100 shares of Series C Convertible Preferred Stock, each of which is convertible into 20,000 shares of Common Stock. Each share of Series C Convertible Stock is entitled to thirteen votes for each share of Common Stock issuable upon conversion of a share of Series C Preferred Stock. The holders of Series C Convertible Preferred Stock, voting separately as a class, also have the right to elect three members to the Board of Directors of the Company. The I. Reich Family Limited Partnership has also purchased a $300,000 6% Convertible Note due July 9, 2004 and a $600,000 6% Secured Note due July 9, 2004 from the Company. The Secured Note is secured by the Company's accounts receivable, inventory and certain intellectual property. Under the Notes, the Company has the option to defer interest payable until the maturity date. The convertible note is convertible into shares of the Company's Common Stock at a conversion price of $.0575 per share. The Company has also issued to the I. Reich Family Limited Partnership a seven-year warrant to purchase 22,220,113 shares of Common Stock of the Company at a price of $.0575 per share. Before joining SpectruMedix, Mr. Reich served as President and Co-Chief Executive Officer of Inamed Corporation, a global surgical and medical device company engaged in the development, manufacturing and marketing of products for the plastic and reconstructive surgery, aesthetic medicine and obesity markets. "I am excited to be joining the SpectruMedix team," Mr. Reich said. "I know that the Company has superior technology and is well regarded by its customers. In addition, the fields of DNA sequencing analysis and high throughput screening analysis offer excellent growth potential. I am confident that with the support of the Board of Directors and the Company's outstanding employees, including its researchers and the management team, we can increase sales and put SpectruMedix on the path to profitability." "We welcome Ilan Reich's interest in our Company, and we look forward to working with him to take SpectruMedix to the next phase in its development. We are delighted and fortunate to have attracted an executive with his demonstrated talents," said Stephen Wertheimer, a member of the Board of Directors. "While we are highly appreciative of Dr. Adlerstein's contributions to the development of the Company's technology, at this stage, the Company needs management that is oriented toward increasing sales and profitability.<< snip Cheers, Tuck